Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
4BU2wxREHYYN2aNq